← Leaderboards
Christian S Hendershot
University Of Washington
$2,320,330
Attributed
$5,020,514
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2006–25$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,020,514 · 8
By mechanism
U01$2,828,440 · 1
R21$2,014,328 · 5
F31$97,692 · 1
F32$80,054 · 1
Top collaborators
- Eric D Claus4 shared
- Bernard Le Foll2 shared
- Andrea C King1 shared
- Sherry Mckee1 shared
- Joseph P Schacht1 shared
Most similar at University Of Washington
Same institution · by research overlap
- David A. D'alessio$11,554,583
- David E Cummings$4,675,421
- David R Flum$28,560,382
- Jisun Paik$3,392,693
- Margaret McLean Heitkemper$19,105,705
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseAlcohol ConsumptionAlcoholsIndexingBaseReportingPre-ClinicalDrinkingAgonistPharmaceutical PreparationsPlacebosBehaviorPhenotypeBehavioralAccountingAlcohol Use DisorderAlcohol ResponseImpulsivityPharmacotherapyHeavy DrinkingParticipantGeneticHigh RiskCharacteristics
Grant awards (16)
Multi Site Randomized Trial of a GLP-1/GIP Receptor Agonist for Smoking Cessation$2,828,440
U01 · FY2025 · DA · contact PI
Phase II Evaluation of Tirzepatide in Adults with Alcohol Use Disorder and Overweight or Obesity$184,782
R21 · FY2025 · AA · contact PI
Phase II Evaluation of Tirzepatide in Adults with Alcohol Use Disorder and Overweight or Obesity$211,247
R21 · FY2024 · AA · contact PI
Effects of Semaglutide on Nicotine Intake and Smoking Lapse$235,155
R21 · FY2021 · DA · contact PI
Human Laboratory Screening of Semaglutide for Alcohol Use Disorder$225,436
R21 · FY2021 · AA · contact PI
Behavioral mechanisms of lorcaserin treatment for smoking cessation$225,803
R21 · FY2019 · DA · contact PI
Human Laboratory Screening of Lorcaserin in Smokers with Alcohol Use Disorder$214,657
R21 · FY2019 · AA · contact PI
Role of Histamine H3 Receptors on Alcohol Responses$141,497
R21 · FY2019 · AA
Role of Histamine H3 Receptors on Alcohol Responses$141,497
R21 · FY2018 · AA
Sensitivity to Intravenous Ethanol: Neuroimaging and Behavioral Phenotypes$196,448
R21 · FY2012 · AA
Sensitivity to Intravenous Ethanol: Neuroimaging and Behavioral Phenotypes$237,806
R21 · FY2011 · AA
Alcohol and HIV risk: Genetic and endophenotype approaches$32,649
F32 · FY2010 · AA · contact PI
Alcohol and HIV risk: Genetic and endophenotype approaches$47,405
F32 · FY2009 · AA · contact PI
ALDH2, ADH1B and Alcohol Expectancies in Asian Americans$32,564
F31 · FY2008 · AA · contact PI
ALDH2, ADH1B and Alcohol Expectancies in Asian Americans$32,564
F31 · FY2007 · AA · contact PI
ALDH2, ADH1B and Alcohol Expectancies in Asian Americans$32,564
F31 · FY2006 · AA · contact PI